Submission

To the House of Commons Standing Committee on Health

Women’s Health Study

Expert Recommendations for Breast Cancer Screening in Canada

Jean M Seely, MDCM, FRCPC, FSBI, FCAR,
Full Professor of Radiology, University of Ottawa

Paula Gordon, OC, OBC, MD, FRCPC, FSBI
Clinical Professor of Radiology, University of British Columbia

Shushiela Appavoo, MD, FRCPC
Associate Clinical Professor Department of Radiology and Diagnostic Imaging, University of Alberta

Martin J. Yaffe PhD, C.M., FRSC
Professor, Department of Medical Biophysics, University of Toronto
Senior Scientist, Physical Sciences Platform, Sunnybrook Research Institute
Co-Director, Imaging Research Program
Ontario Institute for Cancer Research

Anna N Wilkinson, MSc, MD, CCFP, FCFP
Associate Professor, University of Ottawa

Jennie Dale, MBA, Cofounder and Executive Director,
Dense Breasts Canada
**Why is breast cancer screening important?**

One in eight women will develop breast cancer. In 2022, 28,600 Canadian women were diagnosed with breast cancer and 5,500 died from it \[^1\]. Early detection by screening helps to decrease the likelihood of death. Screening has been shown to decrease breast cancer mortality in Canada by 40% overall and 44% in women aged 40-49 \[^2\]. Living in a province that includes screening for women in their 40s is associated with a 1.9% increase in 10-year net survival \[^3\]. This is a similar benefit to tamoxifen, a drug used for patients with hormone positive breast cancer. Similarly, living in these provinces is associated with a lower stage of breast cancer at diagnosis in women in their 40s and 50s \[^23\]. In addition to decreasing deaths, early-stage diagnosis means less need for harsh treatments \[^4\], such as mastectomy and chemotherapy, and less disfiguring lymphedema (a permanent swelling of the arm). There is also less need for the very costly drugs used for treating advanced cancer. Early detection means better quality of life for women with cancer.

**What do experts recommend?**

The Canadian Association of Radiologists \[^5\] and the Canadian Society of Breast Imaging, as well as expert North American academic societies \[^6\] recommend screening annually starting at age 40 \[^7\]. Seventeen percent of breast cancers are \[^8\] diagnosed in women aged 40-49, and a quarter of all years of life lost \[^9\] to breast cancer are to women diagnosed in their 40s. Screening women starting from age 40 results in the greatest life years gained and saves the most lives from breast cancer. Women with mammographically dense breast tissue should have annual mammograms \[^10\] and be offered additional MRI or ultrasound screening \[^11\] because dense tissue increases the risk of developing cancer as well as the risk that a cancer can be hidden on a mammogram. Supplemental screening with ultrasound \[^12\] or MRI \[^13\] has been shown to decrease interval cancers. These are the cancers diagnosed usually as a lump, after a negative screening mammogram (in the interval between planned mammograms). A reduced interval cancer rate is considered a surrogate measure of mortality reduction \[^14\].

**What does the Canadian Task Force on Preventive Health Care (Task Force) recommend?**

The 2018 breast screening guidelines \[^15\] recommend against screening women aged 40-49, and recommend screening women 50-74 years every 2-3 years. They say that women should not do breast self-exams, that family doctors and nurse practitioners should not do routine breast exams, and that there is no evidence to support supplemental screening for women with dense breasts. Estimates using well validated Canadian and US computer models demonstrate that not screening women aged 40-49 will result in over 400 avoidable deaths every year \[^16\]. Screening women 50+ only every 2-3 years, and not performing supplemental screening for women with dense breasts would bring that to a total of over 1000 avoidable deaths annually.
Why is there a difference between what experts recommend and what the Task Force recommends?

While Task Force members are experts in their own fields, they are not breast cancer experts or specialists in fields directly related to breast cancer. They are mainly family physicians. There are some specialists, but they do not participate in guidelines in their own areas of expertise. For example, a nephrologist (kidney specialist) chaired both the 2011 and 2018 Task Force guidelines on breast cancer screening. With lack of expert clinical involvement there are errors in the choice of and interpretation of evidence; clinical context is lacking in the guidelines.

The current guidelines were issued in 2018. They and all the prior guidelines were largely based on research from the 1960s to the 1980s called randomized clinical trials, all of which were performed in Europe and North America, mainly with white subjects. It is known that Black, Asian, and Hispanic women develop breast cancer younger than white women. Their peak incidence is in the mid-forties (Figure). Black women are more likely to develop aggressive cancers, and are 40% more likely to die of breast cancer. White women are the only group whose peak incidence is older than age 50. Preliminary data with Stats Canada (not yet published) suggests the same findings in Canada. If we are to give equitable access to early detection to all women, it is essential that screening begin at age 40. Moreover, breast cancer is increasing in younger women across the globe, so data from the 1960s to 1980s is outdated. All women at average risk should have access to screening mammography at age 40.
The Task Force stated that it had analyzed the “benefits” and “harms” of mammograms, and concluded that the balance between benefit and harm was less favourable for younger women, than for older women. Given that the benefits include 44% fewer breast cancer deaths[^21], and better quality of life, you might wonder what the “harms” are. The one they’re most concerned about is the anxiety that women experience, if they are recalled after a screening mammogram for additional tests, and they pejoratively call these “false positives.” A better term would be “recalls for further imaging” and these happen with all screening tests. The anxiety is transient, and dissipates quickly, given that 95% of recalled women[^22] are told that they do not have cancer, after the additional tests. The Task Force gives a false equivalence to these false alarms: in the benefits to harms weighting, they equate transient anxiety to avoidable death.

The Task Force changed the recommendation in 2011 to not routinely screen women in their 40s. Prior to that the recommendation was to encourage dialogue and choice for women in their 40s. Unfortunately, the Task Force is not accountable for its guidelines, and does not research the outcomes of their guidelines or consider data showing the impact (positive or negative) of its actions. Canadian data confirm that in provinces/territories where women do not have access to screening until age 50, that women are significantly more likely to be diagnosed with more advanced cancers (associated with poorer survival) from age 40-59, than in jurisdictions that start screening at age 40[^23]. And there was a 10.3% increase in stage IV breast cancer[^23] in women in their 50s and 10.8 % increase in women in their 40s between 2011 and 2020. This is especially important given that treatment costs for advanced disease have increased exponentially in the past ten years[^24].
Unfortunately, the federal government does not provide oversight for the Task Force guidelines. Both the Health Ministry and the Public Health Agency of Canada have repeatedly stated that they are at arm’s length from the Task Force, and they decline to intervene. Most Canadians believe that their healthcare guidance is developed by specialists in the appropriate fields and are disappointed to learn that specialists are largely excluded from guideline development.

As the Task Force has no accountability structure, the errors in its guideline have persisted for years. The Task Force has previously asked for input from experts, but ignored the submissions. For example, the Pan Canadian Study of Canadian breast screening programs was recommended as pertinent to the 2018 revision by multiple consulted content experts. It is the largest observational screening program study in the world and uniquely pertinent to the Canadian population, yet it was neither in the references, nor in the list of excluded evidence for the 2018 guideline.

The Ministry recently provided $500,000 funding to expedite the next review, and the Task Force has ostensibly consulted more experts for evidence review and working group teams, and included patient partners, and public submissions of evidence. Unfortunately, however, these experts and patients have no voting capacity on the guideline panel. If past behaviour predicts future behaviour, it is unlikely that such expert input will be meaningfully incorporated in the creation of the guideline update.

**Why does this matter?**

The Task Force recommendations strongly influence provincial clinical practice guidelines and women’s access to screening across the country. The existence of Task Force guidelines whose trustworthiness is questionable has led to variability in screening policies across provinces and territories and this, in turn, has led to inequity in access for women. Women in some provinces can access screening at 40, while others cannot. This has resulted in differences in stage at diagnosis for women, based on the province in which they live, which affects their survival.

There are many women whose cancers could have been caught earlier if content expert guidelines were used instead of Task Force guidelines. In particular, the avoidable late-stage diagnoses in younger women have a large impact on their families and workplaces. There is a deep and generational trauma and resonance for the families of these women.

**What are the Guidelines internationally?**

For screening mammography, 7 countries start screening at age 40: Iceland, Sweden, USA, Brazil, Japan, Korea, and Turkey. Austria, Cyprus, Hungary, Israel, Columbia, and Portugal start at 45, but women in Austria and Hungary may opt in to start at 40. The remainder start at age 50 and screen every 2 years, except for the UK which screens every 3 years.
Supplemental screening for women with dense breasts is recommended in Austria, Bulgaria, Croatia, Cyprus, France, Greece, Hungary, Lithuania, Serbia, Spain, and Switzerland.

This chart shows that although the incidence of breast cancer in Canada is lower than Norway, Austria, Sweden and the USA, our mortality is higher \[^{28}\].

<table>
<thead>
<tr>
<th>Country</th>
<th>Age standardized Incidence/100,000</th>
<th>Age standardized Mortality/100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norway</td>
<td>83.1</td>
<td>10.7</td>
</tr>
<tr>
<td>Australia</td>
<td>96</td>
<td>11.7</td>
</tr>
<tr>
<td>Sweden</td>
<td>83.9</td>
<td>12.0</td>
</tr>
<tr>
<td>United States</td>
<td>90.3</td>
<td>12.4</td>
</tr>
<tr>
<td>Canada</td>
<td>82.1</td>
<td>13.3</td>
</tr>
<tr>
<td>UK</td>
<td>87.7</td>
<td>14.0</td>
</tr>
<tr>
<td>France</td>
<td>99.1</td>
<td>15.6</td>
</tr>
<tr>
<td>World</td>
<td>47.8</td>
<td>13.6</td>
</tr>
</tbody>
</table>

**What are the financial costs of poor screening practices?**

Inadequate screening results in avoidable late-stage diagnosis. We now know the financial costs of late-stage diagnosis. Researchers recently derived costs \[^{24}\] (see table 1) for each stage and molecular subtype of breast cancer, and using Ontario figures, showed the exponentially increased costs with increasing stage. Metastatic (stage IV) breast cancer was up to 11x more costly to treat than stage I breast cancer: $25,247 for stage I; and as high as $516,415 for stage IV. Moreover, those are underestimates because they are based on the stage at diagnosis, and do not account for women diagnosed at earlier stages who progress to and are treated for stage IV.

<table>
<thead>
<tr>
<th>Subtype</th>
<th>DCIS</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR+</td>
<td></td>
<td>28,201</td>
<td>60,289</td>
<td>117,269</td>
<td>256,693</td>
</tr>
<tr>
<td>HR+/HER2+</td>
<td>14,505</td>
<td>C$ 56,401</td>
<td>76,547</td>
<td>86,853</td>
<td>516,415</td>
</tr>
<tr>
<td>HER2+</td>
<td></td>
<td>47,201</td>
<td>67,136</td>
<td>75,954</td>
<td>514,992</td>
</tr>
<tr>
<td>TN</td>
<td>25,247</td>
<td>101,811</td>
<td>C110,798</td>
<td>193,490</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>14,505</td>
<td>39,263</td>
<td>76,446</td>
<td>97,668</td>
<td>370,398</td>
</tr>
</tbody>
</table>

\[Table 1. Cost per treatment of case of breast cancer by subtype and stage. All costs in 2023C\$.\]
Recommendations specific to breast cancer screening

Experts recommend screening women 40-49 annually and screening women 50 and older every 1 to 2 years for as long as they are in good general health, with a life expectancy of 10 years. They also recommend that women be notified of their breast density and offered supplemental density screening if they have category C or D density. The content experts’ opinions are based on understanding of evidence, along with specialized training, experience, and compassion for our patients.

Recommendations regarding the Task Force

While there is an ongoing revision of the 2018 Task Force breast screening guideline, the chair has publicly demonstrated significant bias against screening women 40-49. The use of biased non-content-experts, excluding experts, places Canadian women at risk. Several reforms are needed.

1. Content experts, who are more aware of the clinical context and changing data, should lead the development of guidelines in their areas of specialty, rather than non-experts.
2. Epidemiology experts should play a supportive role in guideline development.
3. Accountability should be built into the Task Force structure and protocols. This is critical in ensuring that guideline errors are acknowledged and corrected in a timely fashion and that expert advice is not ignored.
References

   https://doi.org/10.1093/jnci/dju261
   https://doi.org/10.1200/jco.23.00348
   https://doi.org/10.1093/jbi/wbz038
   https://doi.org/10.1177/21501327211058322
    https://doi.org/10.1177/08465371211027958
   https://doi.org/10.1177/08465371211011707


28. World Health Organization. (n.d.). *Cancer Today.* Global Cancer Observatory. https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=2&cancer=20&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1